Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABX-1431 in Functional Dyspepsia
NCT02875678Phase 1Terminated
- Sponsor
- Abide Therapeutics
- Start
- Nov 2016
- Primary completion
- Aug 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in functional dyspepsia (FD) comparing ABX-1431 with Placebo (2 arms). Primary endpoint: Area Above the Curve of Intragastric Pressure at Day 1. Started Nov 2016; status: terminated.
02
Drugs
ABX-1431
03
Conditions
functional dyspepsia (FD)
Beyond the preview
Go deeper on NCT02875678.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02875678.